Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Receivables: 2011-2025

Historic Receivables for Lineage Cell Therapeutics (LCTX) over the last 13 years, with Sep 2025 value amounting to $676,000.

  • Lineage Cell Therapeutics' Receivables rose 66.91% to $676,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 21.96%. This contributed to the annual value of $638,000 for FY2024, which is 14.36% down from last year.
  • As of Q3 2025, Lineage Cell Therapeutics' Receivables stood at $676,000, which was up 164.06% from $256,000 recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Receivables registered a high of $51.4 million during Q4 2021, and its lowest value of $77,000 during Q1 2024.
  • In the last 3 years, Lineage Cell Therapeutics' Receivables had a median value of $405,000 in 2024 and averaged $393,000.
  • The largest annual percentage gain for Lineage Cell Therapeutics' Receivables in the last 5 years was 21,129.34% (2021), contrasted with its biggest fall of 99.55% (2021).
  • Over the past 5 years, Lineage Cell Therapeutics' Receivables (Quarterly) stood at $51.4 million in 2021, then slumped by 98.29% to $881,000 in 2022, then decreased by 15.44% to $745,000 in 2023, then decreased by 14.36% to $638,000 in 2024, then surged by 66.91% to $676,000 in 2025.
  • Its Receivables was $676,000 in Q3 2025, compared to $256,000 in Q2 2025 and $213,000 in Q1 2025.